SOUTH SAN FRANCISCO, Calif.,
June 26, 2017 /PRNewswire/
-- Veracyte, Inc. (NASDAQ: VCYT) announced today
that it has been awarded a 2017 Top Workplaces honor by the Bay
Area News Group. This marks the fourth consecutive year that
Veracyte has received this prestigious award, which is based solely
on the results of an annual survey of Bay Area-company
employees.
"We are honored and humbled to receive this award and grateful
to our employees for their strong enthusiasm and support for
Veracyte," said Bonnie Anderson,
Veracyte's chairman and chief executive officer. "We are passionate
about improving patient care with our genomic tests and believe we
have built a culture that reflects this passion, which is key to
fueling our continued success."
The Top Workplaces award winners are determined by results of an
employee feedback survey administered by WorkplaceDynamics, LLC, a
leading research firm that specializes in organizational health and
workplace improvement. Several key aspects of workplace culture
were measured for the award, including organizational alignment,
effective execution and meaningful connection with employees.
The Bay Area News Group published the complete list of 2017 Top
Workplaces on Sunday, June 25. The
list of winners is available at the Bay Area News Group
website.
Veracyte's corporate and industry leadership has been recognized
consistently over the past several years. In 2016, the company
received the prestigious Edison Award honoring excellence in new
product and service development, marketing, human-centered design
and innovation. Ms. Anderson has also been named to Fast
Company's 2015 list of the "100 Most Creative People in
Business" and was named by the San Francisco Business Times
in 2015 as one of the "Bay Area's Most Admired CEOs."
About Veracyte
Veracyte
(NASDAQ: VCYT) is a leading genomic diagnostics company that is
fundamentally improving patient care by resolving diagnostic
uncertainty with evidence that is trustworthy and actionable. The
company's products uniquely combine genomic technology, clinical
science and machine learning to provide answers that give
physicians and patients a clear path forward without risky, costly
surgery that is often unnecessary. Since its founding in 2008,
Veracyte has commercialized three genomic tests, which are
transforming the diagnosis of thyroid cancer, lung cancer and
idiopathic pulmonary fibrosis and collectively target a
$2 billion market opportunity.
Veracyte is based in South San Francisco,
California. For more information, please visit
www.veracyte.com and follow the company on
Twitter (@Veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo,
and the Afirma logo are trademarks of Veracyte, Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/veracyte-named-a-san-francisco-bay-area-top-workplace-for-fourth-consecutive-year-300479372.html
SOURCE Veracyte